Hospital-acquired Clostridium difficile significantly prolongs the duration of a patient's stay in the hospital by at least 6 days, according to the findings of a study published online December 5, for the Canadian Medical Association Journal.
Hospital-acquired Clostridium difficile significantly prolongs the duration of a patient's stay in the hospital by at least 6 days, according to the findings of a study published online December 5, for the Canadian Medical Association Journal.
Alan J. Forster, MD, MSc, from the University of Ottawa, and colleagues conducted a retrospective observational cohort study to measure the independent association between infection with hospital-acquired C. difficile and time to discharge, accounting for each patient's risk of death upon admission and the variable time each patient spent in the hospital before acquiring the bacteria.
Looking at a single academic hospital between July 1, 2002, and March 31, 2009, researchers identified 1,393 of 136,877 patients who contracted hospital-acquired infection with C. difficile (overall risk 1.02%; 95% CI, 0.97%–1.06%). Of these, 75.5% were identified on or after the 7th day spent in the hospital.
The crude median length of hospital stay was 34 days for patients with hospital-acquired C. difficile and 8 days for those without. The hazard ratio for discharge by day 7 among patients with hospital-acquired C. difficile was 0.55 (95% CI, 0.39–0.70) for patients in the lowest decile of baseline risk of death and 0.45 (95% CI, 0.32–0.58) for those in the highest decile; while the hazard ratios for discharge by day 28 were 0.74 (95% CI, 0.60–0.87) and 0.61 (95% CI, 0.53–0.68), demonstrating that C. difficile had a larger impact on length of stay for patients at higher baseline risk.
"We found that the impact of hospital-acquired C. difficile on length of stay is more conservative than previous estimates have suggested," the authors noted. "Nevertheless, the impact remains large, especially when one considers the aggregated impact."
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Sets Goal Date for Lymphoma Drug Columvi
December 5th 2024The combination of Columvi, gemcitabine and oxaliplatin is the first CD20xCD3 bispecific antibody to show positive results in a randomized diffuse large B-cell lymphoma phase 3 trial. The FDA’s decision is expected by July 20, 2025.
Read More